Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes

Cisplatin is one of the most effective broad-spectrum anticancer drugs. Its effectiveness seems to be due to the unique properties of cisplatin, which enters cells via multiple pathways and forms multiple different DNA-platinum adducts while initiating a cellular self-defense system by activating or silencing a variety of different genes, resulting in dramatic epigenetic and/or genetic alternations. As a result, the development of cisplatin resistance in human cancer cells in vivo and in vitro by necessity stems from bewilderingly complex genetic and epigenetic changes in gene expression and alterations in protein localization. Extensive published evidence has demonstrated that pleiotropic alterations are frequently detected during development of resistance to this toxic metal compound. Changes occur in almost every mechanism supporting cell survival, including cell growth-promoting pathways, apoptosis, developmental pathways, DNA damage repair, and endocytosis. In general, dozens of genes are affected in cisplatin-resistant cells, including pathways involved in copper metabolism as well as transcription pathways that alter the cytoskeleton, change cell surface presentation of proteins, and regulate epithelial-to-mesenchymal transition. Decreased accumulation is one of the most common features resulting in cisplatin resistance. This seems to be a consequence of numerous epigenetic and genetic changes leading to the loss of cell-surface binding sites and/or transporters for cisplatin, and decreased fluid phase endocytosis.

[1]  Kou-Juey Wu,et al.  Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer , 2010, Clinical Cancer Research.

[2]  D. Ma,et al.  Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. , 2010, Biochemical and biophysical research communications.

[3]  Anutosh Chakraborty,et al.  Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain , 2010, Cell.

[4]  W. Houry,et al.  Hsp90: a chaperone for protein folding and gene regulation. , 2005, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[5]  K Shimizu,et al.  EMX2 is epigenetically silenced and suppresses growth in human lung cancer , 2010, Oncogene.

[6]  F. Esposito,et al.  Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. , 2010, Cancer research.

[7]  Kenneth S Kosik,et al.  MicroRNAs and Cellular Phenotypy , 2010, Cell.

[8]  R. Weinberg,et al.  AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. , 2010, Cancer research.

[9]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[10]  Daohai Zhang,et al.  Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells. , 2010, Experimental cell research.

[11]  M. Gottesman,et al.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. , 2003, Cancer research.

[12]  S. Johnson,et al.  Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.

[13]  Y. Yoshida,et al.  Cisplatin resistance and transcription factors. , 2005, Current medicinal chemistry. Anti-cancer agents.

[14]  Qiang Yu,et al.  B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. , 2010, Cancer cell.

[15]  David Sidransky,et al.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers. , 2010, Cancer research.

[16]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[17]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[18]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[19]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[20]  K. Uematsu,et al.  Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. , 2007, Anticancer research.

[21]  H. Qi,et al.  Heterogeneous SWI/SNF Chromatin Remodeling Complexes Promote Expression of Microphthalmia —Associated Transcription Factor Target Genes in Melanoma , 2009, Oncogene.

[22]  Takako Noguchi,et al.  Tip60 Is Regulated by Circadian Transcription Factor Clock and Is Involved in Cisplatin Resistance* , 2008, Journal of Biological Chemistry.

[23]  J. Hong,et al.  Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. , 2009, Journal of pharmacological sciences.

[24]  C. Leonetti,et al.  Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. , 2004, Biochemical and biophysical research communications.

[25]  S. Lindquist,et al.  Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi , 2005, Science.

[26]  Raghu Kalluri,et al.  The epithelial–mesenchymal transition: new insights in signaling, development, and disease , 2006, The Journal of cell biology.

[27]  A. Thomson,et al.  The mechanism of action of antitumor platinum compounds. , 1979, Progress in nucleic acid research and molecular biology.

[28]  M. Osmak,et al.  Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia. , 2001, Neoplasma.

[29]  M. Santoro,et al.  Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin , 2004, British Journal of Cancer.

[30]  S. Hirohashi,et al.  Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. , 2008, Cancer research.

[31]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[32]  P. Finn,et al.  Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo , 2009, British Journal of Cancer.

[33]  J. Hayes,et al.  The cap'n'collar transcription factor Nrf2 mediates both intrinsic resistance to environmental stressors and an adaptive response elicited by chemopreventive agents that determines susceptibility to electrophilic xenobiotics. , 2011, Chemico-biological interactions.

[34]  M. Gottesman,et al.  The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. , 2008, Annual review of pharmacology and toxicology.

[35]  Y. Assaraf,et al.  Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. , 2010, Biochemical pharmacology.

[36]  M. Gottesman,et al.  Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance , 2010, Journal of cellular physiology.

[37]  Andrey Golubov,et al.  Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin , 2010, International journal of cancer.

[38]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[39]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[40]  I. Pastan,et al.  Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. , 1996, Experimental cell research.

[41]  M. Birnbaum,et al.  Three-amino-acid-loop-extension homeodomain factor Meis3 regulates cell survival via PDK1 , 2010, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Bacik,et al.  Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors , 2004, Molecular Cancer.

[43]  I. Pastan,et al.  Decreased accumulation of [14c]carboplatin in human cisplatin‐resistant cells results from reduced energy‐dependent uptake , 2000, Journal of cellular physiology.

[44]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[45]  F. Esposito,et al.  Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis , 2007, Stress.

[46]  M. Gottesman,et al.  The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. , 2012, Molecular pharmaceutics.

[47]  M. White,et al.  TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. , 2011, Molecules and Cells.

[48]  S. Cohen,et al.  microRNA functions. , 2007, Annual review of cell and developmental biology.

[49]  M. Oren,et al.  p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin , 2011, PloS one.

[50]  H. Izumi,et al.  Transcription factors and drug resistance. , 2005, European journal of cancer.

[51]  Michael M. Gottesman,et al.  Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis , 2010, Proceedings of the National Academy of Sciences.

[52]  F. López-Ríos,et al.  IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer , 2010, Oncogene.

[53]  W. Figg,et al.  Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance , 2008, Cancer biology & therapy.

[54]  Wang Yang DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy , 2010 .

[55]  Zhengtang Chen,et al.  Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. , 2008, Lung cancer.

[56]  N. Sonenberg,et al.  Translational control in stress and apoptosis , 2005, Nature Reviews Molecular Cell Biology.

[57]  B. Györffy,et al.  Acquired cisplatin resistance in the head–neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1 , 2008, International journal of cancer.

[58]  I. Pastan,et al.  Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. , 1995, British Journal of Cancer.

[59]  F. Gago,et al.  Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy , 1998, International journal of cancer.

[60]  Yi Guo,et al.  Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. , 2007, Cancer research.

[61]  M. Kwak,et al.  Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. , 2008, Cancer letters.

[62]  F. Couch,et al.  Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma , 2022 .

[63]  R. Ozols,et al.  Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. , 1993, Cancer research.

[64]  C. Croce Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[65]  M. Gottesman,et al.  SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism , 2008, Molecular Cancer Research.

[66]  Jean-Pierre Gillet,et al.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.

[67]  M. Gottesman,et al.  RAB8 Enhances TMEM205-Mediated Cisplatin Resistance , 2011, Pharmaceutical Research.

[68]  Chun-Yang Fan,et al.  MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel‐induced multidrug resistance , 2011, Head & neck.

[69]  Jiang Shou,et al.  Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA , 2002, Oncogene.

[70]  Jian Zhang,et al.  姜黄素通过下调miR-186*促进人肺腺癌细胞A549/DDP凋亡 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[71]  F. Quelle,et al.  FOXO Transcription Factors Enforce Cell Cycle Checkpoints and Promote Survival of Hematopoietic Cells after DNA Damage , 2009, Molecular Cancer Research.

[72]  S. de Jong,et al.  Effect of novobiocin on cisplatin cytotoxicity and dna interstrand cross‐link formation in a cisplatin‐resistant, small‐cell lung carcinoma cell line , 1993, International journal of cancer.

[73]  Ken Yamamoto,et al.  P300/CBP‐associated factor regulates Y‐box binding protein‐1 expression and promotes cancer cell growth, cancer invasion and drug resistance , 2010, Cancer science.

[74]  J. Liu,et al.  Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. , 2002, Cancer research.

[75]  D. Gibson,et al.  Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts. , 2009, Journal of medicinal chemistry.

[76]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[77]  A. Addario,et al.  Role of microRNAs in drug-resistant ovarian cancer cells. , 2008, Gynecologic oncology.

[78]  S. Howell,et al.  The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. , 2002, Molecular pharmacology.

[79]  M. Serrano,et al.  Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway , 2010, Cell cycle.

[80]  M. Gottesman,et al.  Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells , 2004, British Journal of Cancer.

[81]  J. Li,et al.  MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1 , 2012, Oncogene.

[82]  David I. Watson,et al.  Mir-148a Improves Response to Chemotherapy in Sensitive and Resistant Oesophageal Adenocarcinoma and Squamous Cell Carcinoma Cells , 2011, Journal of Gastrointestinal Surgery.

[83]  K. Kato,et al.  Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells. , 2000, Biochimica et biophysica acta.

[84]  P. Drew,et al.  The proteomic analysis of cisplatin resistance in breast cancer cells. , 2007, Oncology research.

[85]  G. Tsujimoto,et al.  MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma , 2011, Journal of Human Genetics.

[86]  B. Jiang,et al.  miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP , 2012, Cancer Chemotherapy and Pharmacology.

[87]  H. Su,et al.  Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway , 2010, International journal of cancer.

[88]  S. Howell,et al.  Transport of Cisplatin by the Copper Efflux Transporter ATP7B , 2008, Molecular Pharmacology.

[89]  Zhongzhou Yang,et al.  PDK1 Regulates Vascular Remodeling and Promotes Epithelial-Mesenchymal Transition in Cardiac Development , 2010, Molecular and Cellular Biology.

[90]  J. Richter,et al.  Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance , 2010, The Journal of pathology.

[91]  S. Owatari,et al.  Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. , 2007, Cancer research.

[92]  H. You,et al.  Oncogenic H-Ras Enhances DNA Repair through the Ras/Phosphatidylinositol 3-Kinase/Rac1 Pathway in NIH3T3 Cells , 2002, The Journal of Biological Chemistry.

[93]  P. Sharp,et al.  MicroRNA functions in stress responses. , 2010, Molecular cell.

[94]  J. Pignon,et al.  Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program , 2007, Clinical Cancer Research.

[95]  A. Harris,et al.  6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. , 2010, Cancer research.

[96]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[97]  Y. Doki,et al.  Overexpression of miR-200c Induces Chemoresistance in Esophageal Cancers Mediated Through Activation of the Akt Signaling Pathway , 2011, Clinical Cancer Research.

[98]  M. Gottesman,et al.  Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. , 2004, Molecular pharmacology.

[99]  E. Reed Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. , 1998, Cancer treatment reviews.

[100]  Bin Han,et al.  Enhanced Expression of PCAF Endows Apoptosis Resistance in Cisplatin-Resistant Cells , 2010, Molecular Cancer Research.

[101]  Myeong Sup Lee,et al.  Rab35 Mediates Transport of Cdc42 and Rac1 to the Plasma Membrane during Phagocytosis , 2010, Molecular and Cellular Biology.

[102]  Wei Zhu,et al.  miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2 , 2012, Medical Oncology.

[103]  R. Fuchs,et al.  Spectrum of cisplatin-induced mutations in Escherichia coli. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[105]  Donna D. Zhang,et al.  Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism , 2011, Proceedings of the National Academy of Sciences.

[106]  S. Tsao,et al.  Targeting NF-κB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer , 2009, Molecular Cancer Therapeutics.

[107]  H. Ngan,et al.  Changes in p21WAF1, pRb, Mdm-2, Bax and Bcl-2 expression in cervical cancer cell lines transfected with a p53 expressing adenovirus. , 2000, European journal of cancer.

[108]  H. Hollema,et al.  Heat‐shock‐protein‐27(HSP27) expression in ovarian carcinoma: Relation in response to chemotherapy and prognosis , 1999, International journal of cancer.

[109]  Ping H Wang,et al.  Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. , 2003, Journal of molecular and cellular cardiology.

[110]  Xia Shan,et al.  miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines , 2010, International journal of cancer.

[111]  Å. Andreassen,et al.  Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles , 2007, Molecular Cancer.

[112]  B. Rosenberg Platinum coordination complexes in cancer chemotherapy , 1973, Naturwissenschaften.

[113]  B. Kaina,et al.  The Ras-related Small GTP-binding Protein RhoB Is Immediate-early Inducible by DNA Damaging Treatments (*) , 1995, The Journal of Biological Chemistry.

[114]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[115]  I. Pastan,et al.  Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. , 1998, Cancer research.

[116]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[117]  Marina Kriajevska,et al.  SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer , 2009, Proceedings of the National Academy of Sciences.

[118]  W. Gianni,et al.  Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. , 2010, Current cancer drug targets.

[119]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[120]  Zhengtang Chen,et al.  Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. , 2008, Biochemical and biophysical research communications.

[121]  D. Gibson The mechanism of action of platinum anticancer agents--what do we really know about it? , 2009, Dalton transactions.

[122]  S. Howell,et al.  Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin , 2006, Molecular Pharmacology.

[123]  G. Fu,et al.  MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance , 2011, Journal of Cell Science.

[124]  M. Kris,et al.  Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[125]  S. Howell,et al.  Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs , 2010, Molecular Pharmacology.

[126]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[127]  Buzz Baum,et al.  Transitions between epithelial and mesenchymal states in development and disease. , 2008, Seminars in cell & developmental biology.

[128]  S. Narod BRCA mutations in the management of breast cancer: the state of the art , 2010, Nature Reviews Clinical Oncology.

[129]  M. Gottesman,et al.  Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines , 2003, British Journal of Cancer.

[130]  M. Gottesman,et al.  Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. , 2004, Molecular pharmacology.

[131]  S. Chatterjee,et al.  Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation. , 1999, Biochemical and biophysical research communications.

[132]  M. Gottesman,et al.  Identification by Functional Cloning from a Retroviral cDNA Library of cDNAs for Ribosomal Protein L36 and the 10-kDa Heat Shock Protein that Confer Cisplatin Resistance , 2006, Molecular Pharmacology.

[133]  A. Zaas,et al.  Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease , 2009, Proceedings of the National Academy of Sciences.

[134]  H. Hollema,et al.  89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922 , 2010, Journal of Nuclear Medicine.

[135]  B. Blair,et al.  Copper Transporter 2 Regulates Endocytosis and Controls Tumor Growth and Sensitivity to Cisplatin In Vivo , 2011, Molecular Pharmacology.

[136]  M. Gottesman,et al.  Endocytic recycling compartments altered in cisplatin-resistant cancer cells. , 2006, Cancer research.

[137]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[138]  Johan Hansson,et al.  Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling* , 2003, The Journal of Biological Chemistry.

[139]  Qi-En Wang,et al.  Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment. , 2011, Mutation research.

[140]  G. Mills,et al.  Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase , 2010, PloS one.

[141]  J. Beijnen,et al.  Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)* , 2001, The Journal of Biological Chemistry.

[142]  H. You,et al.  Protect Cells from Platinum-Based Anticancer Agents Oncogenic HRas UpRegulates Expression of ERCC 1 to Updated , 2004 .

[143]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.